>
Pro Medicus logo

PME - Pro Medicus Share Price

A$42.38 -3.6  -7.8%

Last Trade - 7:10am

Sector
Healthcare
Size
Large Cap
Market Cap Ā£2.67bn
Enterprise Value Ā£2.64bn
Revenue Ā£33.0m
Position in Universe 122nd / 1907
Bullish
Bearish
Unlock PME Revenue
Momentum
Relative Strength (%)
1m +3.10%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -5.63%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
113.1
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
17.6 27.6 31.6 33.9 50.3 57.0 69.9 94.4 +26.5%
+108.6 +100.1 +42.5 +6.7 +91.7 +20.6 +35.8 +41.7
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, ProMedicus Limited revenues increased 8% to A$31.7M. Netincome increased 12% to A$13.5M. Revenues reflect Australiasegment increase of 23% to A$6.6M, Europe segment increaseof 49% to A$2.5M, North America segment increase of 1% toA$22.6M. Net income benefited from Europe segment incometotaling A$2.3M vs. loss of A$675K, Australia segmentincome increase of 2% to A$15.2M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for PME
Graphical History

Revenue

PME Revenue Unlock PME Revenue

Net Income

PME Net Income Unlock PME Revenue

Normalised EPS

PME Normalised EPS Unlock PME Revenue

PE Ratio Range

PME PE Ratio Range Unlock PME Revenue

Dividend Yield Range

PME Dividend Yield Range Unlock PME Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
PME EPS Forecasts Unlock PME Revenue
Profile Summary

Pro Medicus Ltd is an Australia-based company that provides health imaging information technology (IT). The Company provides a range of health imaging software and services to hospitals, imaging centers and health care groups. It offers its solutions under the brand, Visage. Its segments include Australia, Europe and North America. The Visage product line comprises solutions for radiology information systems (RIS)/practice management, healthcare imaging and e-health. These systems can be used either individually or in combination by radiologists and other medical imaging professionals to interpret the images created by medical imaging equipment, such as X-Ray and Ultrasound machines and computed tomography (CT) and magnetic resonance imaging (MRI) scanners and communicate the results to their referring clinicians. Its products include Visage RIS, Visage 7, Visage Ease Pro and Visage Ease.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated September 7, 1983
Public Since October 10, 2000
No. of Shareholders: 9,830
No. of Employees: 79
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index S&P/ASX All Ordinaries , S&P/ASX 200 , S&P/ASX 300 , ASX Small Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 104,211,574
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PME Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PME
Upcoming Events for PME
Frequently Asked Questions for Pro Medicus
What is the Pro Medicus share price?

As of 7:10am, shares in Pro Medicus are trading at A$42.38, giving the company a market capitalisation of Ā£2.67bn. This share price information is delayed by 15 minutes.

How has the Pro Medicus share price performed this year?

Shares in Pro Medicus are currently trading at A$42.38 and the price has moved by 73.4% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Pro Medicus price has moved by 29.7% over the past year.

What are the analyst and broker recommendations for Pro Medicus?

Of the analysts with advisory recommendations for Pro Medicus, there are there are currently 0 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Pro Medicus is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Pro Medicus next release its financial results?

Pro Medicus is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Pro Medicus dividend yield?

The Pro Medicus dividend yield is 0.28% based on the trailing twelve month period.

Does Pro Medicus pay a dividend?

Last year, Pro Medicus paid a total dividend of 0.13, and it currently has a trailing dividend yield of 0.28%. Looking ahead, Pro Medicus has not announced an ex-dividend date yet.

When does Pro Medicus next pay dividends?

Pro Medicus has yet to annouce their ex-dividend date. The historic dividend yield on Pro Medicus shares is currently 0.28%.

How do I buy Pro Medicus shares?

To buy shares in Pro Medicus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopediaā€™s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Pro Medicus?

Shares in Pro Medicus are currently trading at A$42.38, giving the company a market capitalisation of Ā£2.67bn.

Where are Pro Medicus shares listed? Where are Pro Medicus shares listed?

Here are the trading details for Pro Medicus:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: PME
What kind of share is Pro Medicus?

Based on an overall assessment of its quality, value and momentum, Pro Medicus is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Pro Medicus share price forecast 2021?

Shares in Pro Medicus are currently priced at A$42.38. At that level they are trading at 0.18% premium to the analyst consensus target price of 0.00.

Analysts covering Pro Medicus currently have a consensus Earnings Per Share (EPS) forecast of 0.3 for the next financial year.

How can I tell whether the Pro Medicus share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pro Medicus. Over the past six months, the relative strength of its shares against the market has been 20.74%. At the current price of A$42.38, shares in Pro Medicus are trading at 31.34% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Pro Medicus PE Ratio?

The Pro Medicus PE ratio based on its reported earnings over the past 12 months is 0.196k. The shares are currently trading at A$42.38.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Pro Medicus?

Pro Medicus's management team is headed by:

Sam Hupert - CEO
Anthony Hall - EDR
Danny Tauber - GMG
Peter Kempen - NEC
Clayton Hatch - CFO
Malte Westerhoff - CTO
Brad Levin - GMG
Anthony Glenning - NID
Leigh Farrell - NID
Sean Lambright - OTH
Teresa Gschwind - OTH
Deena Shiff - NID
Who are the major shareholders of Pro Medicus?

Here are the top five shareholders of Pro Medicus based on the size of their shareholding:

Hupert (Sam Aaron) Individual Investor
Percentage owned: 26.04% (27.1m shares)
Hall (Anthony Barry) Individual Investor
Percentage owned: 26.01% (27.1m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 1.04% (1.08m shares)
Goldman Sachs Asset Management, L.P. Investment Advisor
Percentage owned: 0.76% (797k shares)
Goldman Sachs International Small Cap Insights Fund Mutual Fund
Percentage owned: 0.74% (771k shares)
Similar to PME
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.